GlassScriptPhysician profile
Shehnaz Rizvi
NPI 1619957420
$1,948.94
in general payments reported to CMS, 2019-2025
25 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $148 · 2021: $392 · 2022: $296 · 2023: $403 · 2024: $263 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.17 | 2020-2025 | Rinvoq, Ubrelvy, Skyrizi |
| Glaxosmithkline, LLC. | $125.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $109.48 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $106.68 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $101.69 | 2020-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $95.03 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $90.23 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $82.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.93 | 2019-2020 | |
| Exact Sciences Corporation | $60.76 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $56.18 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.38 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.88 | 2023 | Gattex |
| Ucb, INC. | $34.28 | 2024 | Cimzia |
| Lundbeck LLC | $31.12 | 2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $24.00 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medtronic, INC. | $22.91 | 2023 | Interstim |
| Otsuka America Pharmaceutical, INC. | $22.77 | 2024 | Rexulti |
| Boston Scientific Corporation | $21.87 | 2024 | Watchman Flx |
| Genentech USA, INC. | $16.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.29 | 2022 | |
| Eisai INC. | $16.20 | 2021 | |
| Pfizer INC. | $16.14 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehnaz Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.